Expert Interview
Looking at the potential of Monte Rosa's Molecular Glue Degrader, MRT-2359, for the treatment of Prostate Cancer
Ticker(s): GLUE, ALPMF, PFE, JNJ, AMGN, NVSInstitution: Moffitt
- Genitourinary Oncologist and Interim Vice Chair at Moffitt, Clinical research director of Moffitt Cancer center's geniourinary program.
- Manages 350 patients with prostate cancer.
- Primary Research interests is integrating tumor evolution dynamics into the treatment of advanced prostate cancer, and has been PI and co-investigator in >50 clinical studies since 2010.
Roughly how many patients do you treat with prostate cancer
Please describe your background and practice setting
Added By: ben_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of MRT-2359, what would it be and why?
Added By: ben_adminWhat is your opinion the response rate and safety profile of MRT-2359?
Added By: ben_adminWhere would MRT-2359 fit into your treatment algorithm of prostate cancer if it was approved?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
